EUVIMEDEUVIMED entdecken
Fallbericht

Synergistic Immune-Mediated Anti-tumour Effect of Dostarlimab and Radiotherapy in the Management of MSI-H/dMMR Endometrial Cancer: A Case Report

Giuseppa Scandurra, Valentina Lombardo, Francesco Marletta, Giulia Marletta, Emanuele Buffettino, Milena Tomaselli, Placido Lanza, Gabriele Corsale, Giacomo Calcara, Domenico Patanè, Paolo Scollo, Basilio Pecorino

EMJ Oncology · 2023

DOI: 10.33590/emjoncol/10300406 ↗

Kurz gefasst

Fallbericht in der Zeitschrift EMJ Oncology, 2023. Verfasst von Giuseppa Scandurra und 11 weiteren Autor:innen. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial carcinoma (EC) is the world’s most common gynaecological malignancy and the fourth most common carcinoma in females. Microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) EC is the most represented EC subtype and is strongly associated with higher expression of anti-programmed death 1 (PD-1) receptor levels, potentially making these tumours responsive to anti-PD-1 treatment. This case report describes the screening and treatment strategies of a 67-year-old female diagnosed with EC, which was initially treated with adjuvant therapy with chemotherapy and radiotherapy (RT). However, after the emergence of a secondary tumour lesion in the brain and other secondary body lesions, the patient started dostarlimab therapy (an anti-PD-1 monoclonal antibody) combined with RT, to evaluate a possible synergistic immune-mediated anti-tumour effect. After 5 months of therapy, the instrumental follow-up showed a complete brain lesion response, and 5 months later, a partial response of the body lesions too. In conclusion, this case report outcome supports the combination of RT and immunotherapy to control and manage MSI-H/dMMR ECs.

Zitieren

APA

Scandurra, G., Lombardo, V., Marletta, F., Marletta, G., Buffettino, E., Tomaselli, M., Lanza, P., Corsale, G., Calcara, G., Patanè, D., Scollo, P., & Pecorino, B. (2023). Synergistic Immune-Mediated Anti-tumour Effect of Dostarlimab and Radiotherapy in the Management of MSI-H/dMMR Endometrial Cancer: A Case Report. EMJ Oncology. https://doi.org/10.33590/emjoncol/10300406

Vancouver

Scandurra G, Lombardo V, Marletta F, Marletta G, Buffettino E, Tomaselli M, et al. Synergistic Immune-Mediated Anti-tumour Effect of Dostarlimab and Radiotherapy in the Management of MSI-H/dMMR Endometrial Cancer: A Case Report. EMJ Oncology. 2023. doi:10.33590/emjoncol/10300406

BibTeX
@article{Scandurra2023,
  author = {Scandurra, Giuseppa and Lombardo, Valentina and Marletta, Francesco and Marletta, Giulia and Buffettino, Emanuele and Tomaselli, Milena and Lanza, Placido and Corsale, Gabriele and Calcara, Giacomo and Patanè, Domenico and Scollo, Paolo and Pecorino, Basilio},
  title = {Synergistic Immune-Mediated Anti-tumour Effect of Dostarlimab and Radiotherapy in the Management of MSI-H/dMMR Endometrial Cancer: A Case Report},
  journal = {EMJ Oncology},
  year = {2023},
  doi = {10.33590/emjoncol/10300406}
}
Kostenlos starten →